Yahoo Finance Global Migraine Competitive Landscape Market Report 2021: 90 Drugs in the Pipeline with 84% Molecules Present in Early Stage Development
Dublin, April 21, 2021 (GLOBE NEWSWIRE) -- The "Migraine - Competitive Landscape in 2021" report has been added to ResearchAndMarkets.com's offering.
There are 90 drugs in the pipeline with 84% molecules present in early stage development.
In migraine, 5-hydroxytryptamine (5-HT) receptor is a major focus of drug developers. Big Pharma dominates R&D in this indication, with Eli Lilly leading the way. The rise in treatment receiving population and increasing preference for branded therapies will drive the market's growth over the next six years, but the high cost of branded therapies is expected to limit their uptake.
This reports provides a data-driven overview of the current and future competitive landscape in migraine therapeutics.
Scope
Disease epidemiology
Marketed drugs assessment
Pipeline drugs assessment
Clinical trials assessment
Commercial assessment
Social media overview
Digital marketing overview
The accompanying Excel file includes the following datasets -
Marketed products exported from the publisher's Pharmaceutical Intelligence Center
Pipeline-stage products exported from the publisher's Pharmaceutical Intelligence Center
Upcoming catalysts in the migraine market exported from the Catalyst Calendar on the publisher's Pharmaceutical Intelligence Center
A list of patent expiry dates for migraine products
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global migraine market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global migraine market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Topics Covered:
1 Preface
1.1 Table of Contents
1.2 Abbreviations
1.3 Related Reports
1.4 Upcoming Related Reports
2 Executive Summary
2.1 Key Findings
2.2 Key Events
3 Introduction
3.1 Report Scope
3.2 Disease Overview Epidemiology Overview
3.3 Epidemiology
4 Marketed Drugs Assessment
4.1 Marketed Drugs Overview
4.2 Marketed Drug Profiles
5 Pipeline Assessment
5.1 Pipeline Overview
5.2 Pipeline Breakdown by Region
5.3 Pipeline Breakdown by Molecule Type and Target
5.4 Drug Review Designations
5.5 Phase Transition Success Rates
5.6 Likelihood of Approval
6 Clinical Trial Assessment
6.1 Clinical Trials Overview by Phase
6.2 Overview by Region
6.4 Therapy Area Perspective
6.4 Leading Sponsors
6.5 Enrollment Analytics
6.6 Feasibility Analysis
7 Commercial Assessment
7.1 Upcoming Market Catalysts
8 Social Media and Digital Marketing
8.1 Key Twitter Chatter
8.2 Top Branded Websites
8.3 Trust Flow and Citation Flow
9 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/cxdv84
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
